z-logo
Premium
Long‐term outcome of lower extremity lymphedema treated with vascularized lymph node flap transfer with or without venous complications
Author(s) -
Koide Satomi,
Lin ChiaYu,
Chen Courtney,
Cheng MingHuei
Publication year - 2020
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.25602
Subject(s) - medicine , lymphedema , cellulitis , surgery , anastomosis , complication , lymph node , microsurgery , cancer , breast cancer
Background: Vascularized submental lymph node (VSLN) transfer is an emerging approach for extremity lymphedema. This study investigated the long‐term outcome and venous complications of VSLN for unilateral lower extremity lymphedema. Methods: Between 2010 and 2018, patients who underwent VSLN for unilateral lower extremity lymphedema were retrospectively evaluated. Patient demographics, operative records, complications, circumferential improvement, and episodes of cellulitis were analyzed. Further comparisons were performed between different types, numbers, and techniques of venous anastomoses. Results: A total of 75 VSLNs in 70 patients survived, giving a 100% success rate. Six flaps (8%) had venous complications (VC group) and 69 flaps (92%) did not (No‐VC group). There were no statistical differences in types, numbers, and techniques of anastomoses between two groups ( P  = .65, 1, and .56, respectively). At a mean follow‐up of 32.0 ± 23.0 months, mean circumferential improvement and episodes of cellulitis between two groups did not statistically differ significantly ( P  = .31 and .09, respectively). Conclusions: VSLN is an effective treatment for lower extremity lymphedema. The types, numbers of veins, and techniques of venous anastomoses did not statistically affect the venous complication rates. Functional outcomes of the VSLNs were not compromised if venous complications were salvaged promptly.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here